Full-Time

Senior Director Nonclinical Development

Updated on 3/14/2025

Viatris

Viatris

10,001+ employees

Compensation Overview

$151k - $314kAnnually

Expert

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • Minimum of a Bachelor's degree (or equivalent) and 15 years of experience.
  • DVM, PhD or in a biomedical discipline or PharmD degree preferred with 10 years of relevant pharmaceutical experience preferred.
  • Must possess expert knowledge of pharmaceutical drug development requirements for regulatory submissions.
  • Must possess expert in-depth knowledge of product development, analytical sciences, and clinical operations.
  • Must have broad knowledge of GMP, GLP, GCP and the Global Regulatory process for Brand/Specialty and generic product approval.
  • The successful candidate must be team-oriented and have exceptional organizational, oral and written communication, and computer skills.
  • Must be able to interface with others of diverse backgrounds, skills, and interests and to maintain a productive and cooperative working relationship.
  • Must have the ability to provide guidance to the Research and Development, Regulatory, and Business Development project teams, to understand technical problems and to make appropriate recommendations for solutions.
  • Position functions autonomously.
  • Position directly supervises employees.
  • Ability to read and interpret comprehensive and intricate research documents.
  • Ability to write scientific reports and technical correspondence.
  • Ability to work with executives and communicate abstract concepts.
  • Ability to present to a high level of the organization and groups outside of the organization.
  • Ability to solve problems with complex variables through non-standardized solutions that require independent judgment and analysis.
  • Ability to draw inferences and use deductive reasoning with no prescribed procedures to solve complex problems.
  • Proficiency in speaking, comprehending, reading and writing English is required.
Responsibilities
  • Direct all aspects of nonclinical development including staffing, supervising, providing work direction, goal setting, prioritization, etc.
  • Oversee the development of the nonclinical regulatory strategy, design of experiments, interpretation of data and oral and written presentation of results.
  • Oversee the review and approval of all preclinical protocols and final reports for nonclinical development studies and ensure data quality and integrity for preclinical sites.
  • Effectively communicate preclinical findings to project teams, senior management, regulators and other external partners.
  • Oversee the research and construction of regulatory study documents for new and complex product development (i.e., IND/NDA preclinical sections etc.).
  • Represent Viatris and Global Pharmacology and Toxicology in meetings with regulatory agencies.
  • Provide technical support to various departments within the company with respect to pharmacology and toxicology.
  • May perform and serve as a reviewer on toxicological risk assessments for various health based exposure limits (HBELs), such as ADEs, PDEs, ADIs and OELs.
  • Assist in the development and adherence to departmental budget.
  • Review for comprehension relevant Standard Operational Procedures (SOPs).
Desired Qualifications
  • DVM, PhD or in a biomedical discipline or PharmD degree preferred with 10 years of relevant pharmaceutical experience preferred.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • DOJ's clearance of Mylan improves Viatris' public image and reduces legal uncertainties.
  • Consistent dividend policy for five years reflects Viatris' financial stability.
  • Participation in major healthcare conferences boosts Viatris' investor engagement.

What critics are saying

  • Increased competition from biosimilars threatens Viatris' market share.
  • Expiration of key drug patents in 2025 may lead to revenue loss.
  • Reliance on international markets exposes Viatris to geopolitical risks.

What makes Viatris unique

  • Viatris bridges the gap between generics and branded drugs globally.
  • Exclusive licensing with Lexicon enhances Viatris' cardiovascular portfolio outside U.S. and Europe.
  • Viatris' commitment to innovation is evident in its cenerimod research for lupus treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 27th, 2025
Viatris Maintains Dividend Policy For 2025 And Announces Quarterly Dividend

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 3rd, 2025
Viatris To Report Fourth Quarter And Full Year 2024 Financial Results On February 27, 2025

PITTSBURGH, Feb. 3, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc

PR Newswire
Oct 16th, 2024
Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals For Sotagliflozin In All Markets Outside Of The U.S. And Europe

Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases. Leverages Viatris' Unique Global Infrastructure and Expertise. Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the United States and Europe